Antimicrobial resistance in the chronically critically ill patient

Clinics in Chest Medicine

Volumn 22, Issue 1, 2001, Pages 87-103

  Poutsiaka, Debra D ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FLUCONAZOLE; FLUCYTOSINE; IMIPENEM; LINEZOLID; MEROPENEM; OXACILLIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CANDIDA; CANDIDIASIS; CHRONIC PATIENT; COAGULASE NEGATIVE STAPHYLOCOCCUS; CRITICAL ILLNESS; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; HEALTH CARE POLICY; HEALTH SURVEY; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PLASMID; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR;

EID: 0035074018     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70027-7     Document Type: Article

References (190)

1. Bacterial pneumonia in hospitalized patients with HIV infection: The pulmoynary complications, ICU support, and prognostic factors of hospitalized patients with HIV (PIP) Study
2. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model
3. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997
4. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997
5. A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: Early termination due to emergence of resistance to fluoroquinolones
6. Staphylococcus epidermidis and other coagulase-negative staphylococci
7. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit
8. Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems
9. Novel transferable extended-spectrum beta-lactamase (SHV-6) from Klebsiella pneumoniae conferring selective resistance to ceftazidime
10. Epidemiological study of an outbreak due to multidrug-resistant Enterobacter aerogenes in a medical intensive care unit
11. Genetics and mechanisms of glycopeptide resistance in enterococci
12. Selective ceftazidime resistance in Escherichia coli: Association with changes in outer membrane protein
13. Impact of voluntary vs enforced compliance of third-generation cephalosporin use in a teaching hospital
14. Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease
15. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America
16. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia
17. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients
18. Pseudomonas aeruginosa bacteremia: Univariate and multivariate analyses of factors influencing the prognosis in 133 episodes
19. Pseudomonas bacteremia. Retrospective analysis of 410 episodes
20. Colonization and infection with Enterococcus faecalis in intensive care units: The role of antimicrobial agents
21. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance
22. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage
23. Risk factors for nosocomial candidemia: A case-control study in adults without leukemia
24. Systemic infections with Candida sp. and Aspergillus sp. in immunocompromised patients with hematological malignancies: Current serological and molecular diagnostic methods
25. Diagnosis and treatment of bacteremia and intravascular catheter infections
26. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System
27. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa
28. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic
29. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
30. Nosocomial acquisition of beta-lactamase-negative, ampicillin-resistant enterococcus
31. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy
32. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin
33. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface
34. An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies
35. The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary case hospital
36. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation
37. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility
38. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides
39. Mechanisms of bacterial resistance to antibiotics
40. Community-acquired bacteremia in HIV-positive patients: Protective benefit of co-trimoxazole
41. A 25-year study of nosocomial bacteremia in an adult intensive care unit
42. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
43. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection
44. Candida species
45. International conference for the development of a consensus on the management and prevention of severe candidal infections
46. Vancomycin-resistant enterococci
47. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study
48. Aminoglycoside-modifying enzymes in clinical isolates harboring extended-spectrum beta-lactamases
49. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group
50. The changing epidemiology of cystic fibrosis
51. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
52. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence
53. Hospital outbreak of Klebsiella pneumoniae resistant to broadspectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase
54. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals
55. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
56. Guideline for isolation precautions in hospitals
57. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis
58. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection?
59. Antimicrobial-drug resistance
60. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation
61. Experience with quinupristin/dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children
62. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50
63. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin resistant Staphylococcus aureus strain Mu50
64. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care traits in 5 European countries. French and Portuguese ICU Study Groups
65. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus
66. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa
67. The drug-resistant pneumococcus: Clinical relevance, therapy, and prevention
68. The positive predictive value of isolating coagulase-negative staphylococci from blood cultures
69. Control of methicillin-resistant Staphylococcus aureus in the hospital setting
70. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients
71. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
72. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
73. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
74. Bacteremia due to methicillin-resistant staphylococci occurs more frequently in neutropenic patients who received antimicrobial prophylaxis and is associated with higher mortality in comparison to methicillin-sensitive bacteriemia
75. Coagulase-negative staphylococci: Role as pathogens
76. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: Evaluation of a national postmarketing surveillance program
77. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms
78. New mechanisms of bacterial resistance to antimicrobial agents
79. Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli
80. More extended-spectrum beta-lactamases
81. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers
82. Risk factors for candidemia in cancer patients: A case-control study
83. Recovery from staphylococcal septicaemia in neutropenic patients without removal of the previously inserted central venous catheter
84. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases
85. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment
86. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa
87. Epidemiology of the colonization of inpatients and outpatients with ciprofloxacin-resistant coagulase-negative staphylococci
88. Identication of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method
89. The epidemiology of fecal carriage of vancomycin-resistant enterococci
90. Quinupristin/dalfopristin: A review of its use in the management of serious gram-positive infections
91. Microbial threats and the global society
92. Comparison of methicillin-resistant and methicillin-sensitive Staphylococcus aureus bacteremia
93. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
94. Beta-Lactamases in laboratory and clinical resistance
95. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods
96. beta-Lactamases of Pseudomonas aeruginosa
97. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers
98. The growing threat of antibiotic-resistant Streptococcus pneumoniae
99. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital
100. Outbreak of multiply resistant enterobacteriaceae in an intensive care trait: Epidemiology and risk factors for acquisition
101. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
102. Analysis of amikacin-resistant Pseudomonas aeruginosa developing in patients receiving amikacin
103. Sepsisbacteraemia and other infections due to non-opportunistic bacterial pathogens in a consecutive series of 788 patients hospitalized for HIV infection
104. Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units
105. Antimicrobial resistance in staphylococci
106. Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay
107. Quinolone resistance by mutations in chromosomal gyrase genes
108. Spread of vancomycin-resistant enterococci: Why did it happen in the United States?
109. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?
110. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin)
111. Nosocomial outbreaks of multiresistant bacteria: Extended-spectrum beta-lactamases have arrived in North America
112. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics
113. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: Effect of large inocula
114. Nasal colonization with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection
115. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins
116. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group
117. Evidence of interhospital transmission of extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in the United States, 1986 to 1993. The National Nosocomial Infections Surveillance System
118. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting
119. A semi-quantitative analysis of the fecal flora of patients with vancomycin-resistant enterococci: Colonized patients pose an infection control risk
120. Methicillin-resistant staphylococcal colonization and infection in a long-term care facility
121. Novel OXA-10-derived extended-spectrum beta-lactamases selected in vivo or in vitro
122. What can we do about vancomycin-resistant enterococci?
123. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients
124. The changing face of candidemia: Emergence of non-candida albicans species and antifungal resistance
125. Trends in beta-lactam resistance among Enterobacteriaceae
126. Vancomycin-resistant enterococci: Clinical, microbiologic, and epidemiologic features
127. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces
128. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality
129. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
130. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia
131. Methicillin-resistant Staphylococcus aureus: Introduction and spread within a hospital
132. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases
133. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission
134. Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: Are beta-lactamase inhibitors of therapeutic value?
135. Plasmid-meditated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains
136. Hospital-acquired bloodstream infections with Staphylococcus epidermidis. Review of 100 cases
137. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci
138. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections
139. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae
140. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella
141. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: Relapse or reinfection?
142. Survival in patients with nosocomial pneumonia: Impact of the severity of illness and the etiologic agent
143. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes
144. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
145. Emergence of tobramycin-resistant S. epidermidis possessing aminoglycoside modifying enzymes and bacteremic superinfection during empiric therapy of febrile neutropenic episodes
146. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center
147. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility
148. Pseudomonas aeruginosa outbreak in a burn unit: Role of antimicrobials in the emergence of multiply resistant strains
149. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis
150. Gram-negative bacillary bacteremia in human immunodeficiency virus type 1-infected children
151. Significant reduction in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia associated with the institution of a prevention protocol
152. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains
153. The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma care unit
154. Antimicrobial resistance in key bloodstream bacterial isolates: Electronic surveillance with the Surveillance Network Database-USA
155. Beta-lactamases of gram-negative bacteria: New challenges for new drugs
156. Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics
157. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation
158. Detection of extended-spectrum beta-lactamases. The reliability of methods for susceptibility testing as used in Denmark
159. Mupirocin treatment of nasal staphylococcal colonization
160. Society for healthcare epidemiology of America and infectious diseases society of America joint committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals
161. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
162. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: Clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes
163. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998
164. Emergence of vancomycin resistance in Staphylococcus aureus
165. Vancomycin therapy for methicillin-resistant Staphylococcus aureus
166. Blood cultures positive for coagulase-negative staphylococci: Antisepsis, pseudobacteremia, and therapy of patients
167. Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa
168. Detection and reporting of organisms producing extended-spectrum beta-lactamases: Survey of laboratories in connecticut
169. High-level resistance to cefotaxime and ceftazidime in Klebsiella pneumoniae isolates from Cleveland, Ohio
170. Septic shock as a predictor of mortality in bacteremia caused by coagulase-negative staphylococci
171. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients
172. Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns
173. Clinical isolates of Escherichia coli producing TRI beta-lactamases: Novel TEM-enzymes conferring resistance to beta-lactamase inhibitors
174. Species identification and detection of oxacillin resistance in coagulase-negative Staphylococcus blood isolates from neutropenic patients
175. Molecular epidemiology of an SHV-5 extended-spectrum beta-lactamase in enterobacteriaceae isolated from infants in a neonatal intensive care unit
176. Candida infections in bone marrow transplant recipients
177. Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1
178. Plasmid-mediated beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli resistant to ceftazidime
179. A novel chromosomal TEM derivative and alterations in outer membrane proteins together mediate selective ceftazidime resistance in Escherichia coli
180. Risk factors associated with candidemia in the neonatal intensive care unit: A case-control study
181. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults
182. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients
183. Survival of vancomycin-resistant and vancomycin-suseptible enterococci on dry surfaces
184. Methicillin-resistant Staphylococcus aureus: Implications for the 1990s and effective control measures
185. Hospital-acquired candidemia. The attributable mortality and excess length of stay
186. Risk factors for hospital-acquired candidemia. A matched case-control study
187. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes
188. Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium
189. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance
190. Colonization pattern of vancomycin-resistant Enterococcus faecium